ARTICLES BY JAMES MORRIS
-
![Missing Puzzle Piece]( "Human Performance In Biopharma Operations — Your Problem Isn’t Error")
Human Performance In Biopharma Operations — Your Problem Isn’t Error11/9/2020Part 1 of a two-part roundtable discusses key drivers for human performance improvement, lean manufacturing and human performance programs, and perspectives on human performance in the context of the rapid scale-up and production of COVID-19 therapeutics and vaccines.
-
![if not now when]( "5 Operational Priorities For Pharma Companies In The Wake Of COVID-19")
5 Operational Priorities For Pharma Companies In The Wake Of COVID-197/20/2020Consider Gilead’s ramp-up of remdesivir under FDA Emergency Use Authorization, or the efforts of companies racing to bring vaccines and therapeutics for COVID-19 through clinical development, safety and efficacy trials at speeds not seen before. The analogy of changing a tire while driving the vehicle is well known — now picture doing so at 7,000 rpm!
James Morris
James Morris has more than 25 years of pharmaceutical management experience in both plant operations and corporate offices, working with Pfizer, Cilag AG, and Mass Biologics in the U.S. and Europe. He has held positions as deputy director QA/QC and regulatory affairs while at Mass Biologics, director of QA/QC for the Biologics business unit of Cilag AG, and several quality assurance and manufacturing roles with Pfizer, culminating as the head of Quality Assurance for Pfizer in Latina, Italy.